An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)


Dane F., Ozgurdal K., YALÇIN S. S. , Benekli M., Aykan N. F. , Yucel I., ...Daha Fazla

ESMO 17th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 1 - 04 Temmuz 2015, cilt.26 identifier